Focused On-demand Library for Conserved oligomeric Golgi complex subunit 6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9Y2V7

UPID:

COG6_HUMAN

Alternative names:

Component of oligomeric Golgi complex 6

Alternative UPACC:

Q9Y2V7; Q5T0U1; Q6AI19; Q86V49; Q9ULT5

Background:

Conserved oligomeric Golgi complex subunit 6, also known as Component of oligomeric Golgi complex 6, plays a pivotal role in maintaining normal Golgi function. This protein is essential for the proper processing and sorting of proteins, ensuring they reach their correct cellular destinations. Its involvement in glycoprotein biosynthesis underscores its importance in cellular physiology and development.

Therapeutic significance:

The protein is linked to Congenital disorder of glycosylation 2L and Shaheen syndrome, diseases characterized by severe developmental and physiological anomalies. These associations highlight the protein's critical role in human health and disease, making it a potential target for therapeutic intervention. Understanding the role of Conserved oligomeric Golgi complex subunit 6 could open doors to potential therapeutic strategies.